Interestingly, some women are now reporting that GLP-1 medications offer benefits beyond weight management
32 A meta-analysis of randomized clinical trials of semaglutide also did not find an increased risk of acute pancreatitis compared with placebo (odds ratio 0.7, 95% confidence interval 0.51.2) regardless of dose, formulation (injectable or oral), or indication
to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition
Pharmacotherapies for the Treatment of Eosinophilic Esophagitis: State of the Art Review
Significant weight loss typically becomes apparent around 8-12 weeks, with optimal results at 6 months and beyond
This shift in GLP-1 behavior changes allows you to make conscious, rational food choices rather than being driven by instinctual urges